Workflow
舜禹股份扣非净利连亏1年半 2023年上市募资8.6亿元
SHUNYU WATERSHUNYU WATER(SZ:301519) Zhong Guo Jing Ji Wang·2025-10-21 06:59

Core Viewpoint - Shunyu Co., Ltd. (301519.SZ) reported a decline in net profit for the first half of 2025, despite a slight increase in revenue compared to the previous year [1][2]. Financial Performance Summary - In the first half of 2025, the company achieved operating revenue of 326.27 million yuan, representing a year-on-year growth of 6.36% compared to 306.76 million yuan in the same period last year [1][2]. - The net profit attributable to shareholders was -10.53 million yuan, a significant decrease from 20.55 million yuan in the previous year [1][2]. - The net profit after deducting non-recurring gains and losses was -13.20 million yuan, down from 7.62 million yuan year-on-year [1][2]. - The net cash flow from operating activities was -23.30 million yuan, slightly improved from -23.70 million yuan in the same period last year [1][2]. Previous Year Comparison - In 2024, the company reported operating revenue of 65.26 million yuan, a decline of 7.36% from 70.45 million yuan in 2023 [3]. - The net profit attributable to shareholders in 2024 was 1.36 million yuan, down 79.84% from 6.77 million yuan in 2023 [3]. - The net profit after deducting non-recurring gains and losses was -0.15 million yuan, compared to 4.97 million yuan in the previous year, indicating a decrease of 102.97% [3]. - The net cash flow from operating activities in 2024 was -27.81 million yuan, a slight improvement from -28.60 million yuan in 2023 [3]. IPO and Fundraising Details - Shunyu Co., Ltd. was listed on the Shenzhen Stock Exchange's ChiNext board on July 27, 2023, with an issuance of 41.16 million shares at a price of 20.93 yuan per share [4]. - The total funds raised from the IPO amounted to 861.48 million yuan, with a net amount of 737.49 million yuan after deducting issuance costs [4]. - The company planned to use the raised funds for projects including the expansion of micro-dynamic integrated water treatment equipment, R&D center construction, marketing channel development, and working capital supplementation [4].